Elligo raises $16M series B to bring clinical trials to more physicians

A physician in scrubs in a hospital hallway
Elligo just raised $16 million to help it expand its physicians network for potential clinical trial participation. (Getty/NanoStockk)

Elligo Health Research aims to bring clinical studies to the 97% of physicians currently not performing them. Now, with a $16 million series B, it is one step closer to fulfilling that mission.

Elligo uses electronic health records to identify potential trial participants, and provides study infrastructure so that physicians can conduct trials at their own clinics. This model could not only motivate physicians previously hesitant to perform clinical studies due to a lack of knowledge or resources, but also allows patients to stay with their physicians.

“Our programs speak specifically to the medical practices that are hesitant to perform research in their offices due to lack of resources and infrastructure,” said Elligo CEO John Potthoff, Ph.D. “The new funding will help us expand our services and not only make research studies more accessible to physician sites but also streamline data collection and submission processes.”

Free Daily Newsletter

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Elligo, Saama join forces to develop new clinical trial data management platform

The company’s own network currently covers 50 practices, and through a collaboration with EHR platform provider Allscripts, it gains access to over 45,000 physician practices capable of doing research, Potthoff told FierceCRO.

Expanding its network is one side of Elligo’s work, and refining its technology is the other. The company is currently working on implementing new technology with the support of Saama Technologies. The new platform will help better identify eligible patients and investigators and enable trial sponsors to collect patient data from disparate sources in real-time view.

The financing round was led by Hatteras Venture partners and Noro-Moseley Partners, its existing investors as well as FS Healthcare and Excelerate Health Ventures also contributed.